Key facts
- It has raised $16.5M; the latest was Later Stage VC in Dec 2024.
- Notable investors include Shinhan Venture Investment, KDB Capital, Kolon Investment, UTC Investment, Hyundai Venture Investment Corporation — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Apitbio
- ·The full record, as it builds
Funding rounds
No funding rounds for Apitbio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Apitbio
Developer of a biotechnology platform designed to develop anti-cancer drugs. The company's platform develops anti-cancer drugs based on antibodies, such as monoclonal antibodies and double antibodies, through research and antibody therapeutics from screening and discovery to optimization and production, enabling hospitals to treat the unmet medical needs of patients.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2018
- Employees
- 9
- Website
- apitbio.com/
- Ownership
- Privately Held (backing)
Apitbio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Apitbio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Apitbio in its N-PORT filings yet. We sweep new filings monthly.